Phase 1 Study of Radiosensitization using Bortezomib in Patients with Relapsed Non-Hodgkin's Lymphoma receiving Radioimmunotherapy

Study Status

Open to Enrollment

Study Description

The purpose of this study is to determine the appropriate doses of bortezomib and 1311-tositumomab when used in combination, and to learn about the toxicities of the combination treatment in patients with relapsed non-Hodgkin's lymphoma.

Bortezomib is administered to patients twice weekly, with the first dose being given two days prior to the treatment dose of 131I-Tositumomab, and the second dose two days after radioimmunotherapy (RIT), for a total of 5 doses.

Click here to visit our lymphoma blog.

Disease Status and/or Stage

Relapsed or Refractory Non-Hodgkin's Lymphoma

Sponsor

Weill Cornell Medical College

Key Eligibility

  • Men and women, age 18 and older
  • Patients must have relapsed or refractory:
    • Mantle Cell Lymphoma, or
    • Diffuse Large B-Cell Lymphoma, including subtypes:
      • Mediastinal large B-cell
      • Centroblastic
      • Immunoblastic
      • T-cell rich B-cell
      • Anaplastic large B-cell, or
    • Low Grade B-cell non-Hodgkin's Lymphoma
  • Must have received prior systemic therapy for lymphoma
  • Women of childbearing potential and men must agree to use adequate birth control methods prior to study entry and for the duration of study participation
  • More detailed eligibility discussed when you contact the study team

Principal Investigator

Rebecca Elstrom, MD

Contact

Healthy Volunteers

healthy_volunteers.jpg

As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.

Contact Us

For general inquiries, or if you need assistance finding a study, please contact:

Robert Hagerty
Subject Recruitment Manager
Tel: (212) 746-9498
roh2026@med.cornell.edu

Top of page